The goals of therapy for patients with inflammatory bowel disorder include inducing and maintaining a steroid-free remission, preventing and treating the complications of the disease, minimizing treatment toxicity, achieving mucosal healing, and enhancing quality of life.
New drugs are needed because a significant fraction of patients reach the end of the line with existing therapies.
All patients with IBD should receive aggressive ongoing assessment of their inflammatory state and its response to immunomodulators, anti-TNF drugs, and other agents.
A purely dichotomous understanding of whether to start treatment for patients who have IBD with anti-TNF agents is becoming an outdated view.
Even the most experienced and skilled gastroenterologists in the country are struggling to make science-based decisions in this area.
These agents remain the mainstay of therapy for the majority of patients with the disease.
A straightforward discussion drove toward attendees toward the more current understanding of the clinical and genetic overlap between the 2 major forms of IBD.
Extraintestinal manifestations of inflammatory bowel disease affect the musculoskeletal, dermatologic, ocular, renal and pulmonary systems.
Therapy for ulcerative colitis and Crohn disease has been transformed with the introduction of anti–tumor necrosis factor treatment, according to University of Miami authors.